CXCR4 and neoplasm: AMD3100 was administered to melanoma-bearing mice peritumorally to directly evaluate the possible involvement of the CXCL12/CXCR4 pathway in A2BR-mediated effects within tumor environment, minimizing possible systemic effects of this molecule.